Current Headlines

  1. NIH Awards Grants In Cell Pathway Research For New Therapies
    9/17/2014

    The National Institutes of Health (NIH) announced that it has awarded more than $64 million in grants to six research institutions to advance understanding of cellular pathways and help in the development of new treatments.

  2. Akashi Acquires Global Rights To Tarantula Venom DMD Therapy
    9/17/2014

    Akashi announced that it had acquired global rights to GsMTx-4, an amino acid peptide toxin isolated from Grammostola rosea (Chilean rose) tarantula venom, in development with Tonus as a potential therapy for Duchenne Muscular Dystrophy (DMD).

  3. More Vaccines Needed For Tropical Diseases, Study Reveals
    9/17/2014

    There has been quite a clamor recently about the record-setting outbreak of the deadly Ebola virus in West Africa, which has killed over 2,200 people to date and spurred numerous strategies in an effort to control it, including a new vaccine and other experimental drugs.

  4. SELLAS Collaborates With MSK For New WT1 Cancer Vaccine
    9/17/2014

    Swiss-based biopharmaceutical company, SELLAS Life Sciences, announced that it has signed a global collaboration and license agreement with the Memorial Sloan Kettering Cancer Center (MSK) to develop, market, and commercialize MSK's new proprietary WT1 cancer vaccine.

  5. Researchers Discover Gene Targets In Emery-Dreifuss Muscular Dystrophy
    9/17/2014

    An international team of researchers has just discovered new genetic targets responsible for an incurable muscle-wasting disease, Emery-Dreifuss muscular dystrophy (EDMD).

  6. Novartis, University Of Pennsylvania To Build Center For CAR Research
    9/16/2014

    Novartis and the University of Pennsylvania announced their plans to build the Center for Advanced Cellular Therapeutics (CACT) on the Penn Medicine campus in Philadelphia.

  7. Asterias Biotherapeutics, Cancer Research UK To Conduct Clinical Trial Of Lung Cancer Immunotherapy Vaccine
    9/16/2014

    BioTime and its subsidiary Asterias Biotherapeutics announced in a press release that they have agreed to conduct an immunotherapy vaccine trial for lung cancer with Cancer Research UK. The charity’s development and commercialization arm, Cancer Research Technology (CRT), will also participate in the trial of AST-VAC2 in subjects with non-small cell lung cancer. The trial will evaluate toxicity, safety, feasibility, immune response, and clinical outcomes.

  8. New Immunotherapy Vaccine Developed For HER2 Positive Breast Cancer
    9/16/2014

    Researchers at the University of Texas MD Anderson Cancer Center have developed a new and promising immunotherapy breast cancer vaccine candidate, GP2, which prevents disease recurrence in high-risk patients, especially in combination with a powerful immunotherapy drug.

  9. EMD Serono Collaborates With Accelerated Cure Project For MS Research Study
    9/16/2014

    EMD Serono last week announced that it has entered an agreement with the Accelerated Cure Project for Multiple Sclerosis (ACP) to help launch a new MS research program called the Optimizing Treatment—Understanding Progression (OPT-UP) study. The collaborative research study will help advance the understanding of and treatment options for MS, which is a disabling neurological disease affecting more than two million people worldwide.

  10. FUJIFILM Diosynth Biotechnologies Chooses ambr250 System For Optimising Microbial Fermentation
    9/16/2014

    TAP Biosystems (now part of the Sartorius Stedim Biotech Group), a leading supplier of innovative cell culture and fermentation systems for life science applications, is pleased to announce that its ambr250 automated mini bioreactor system is being successfully used at leading Contract Development and Manufacturing Organisation, FUJIFILM Diosynth Biotechnologies, for optimising their microbial fermentations to accelerate scale-up production of protein-based therapeutics.

Newsletter Signup
Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.